Revisiting Helicobacter pylori Eradication: Evolving Evidence and Global Implications for Gastric Cancer Prevention
Gastric cancer (GC) remains the fifth most common malignancy and a leading cause of cancer-related mortality.1 Substantial evidence identifies Helicobacter pylori as a major causal factor in GC development,2 and randomized controlled trials (RCTs) have demonstrated that H pylori eradication therapy reduces GC incidence.3 Accordingly, the International Agency for Research on Cancer has recommended in 2014 that countries consider implementing population-based screen-and-treat programs based on local disease burden, health priorities, and cost-effectiveness.
